Traders purchased shares of Abbott Laboratories (NYSE:ABT) on weakness during trading hours on Friday. $49.00 million flowed into the stock on the tick-up and $38.90 million flowed out of the stock on the tick-down, for a money net flow of $10.10 million into the stock. Of all companies tracked, Abbott Laboratories had the 51st highest net in-flow for the day. Abbott Laboratories traded down ($0.21) for the day and closed at $42.09

A number of research firms have commented on ABT. Barclays PLC reaffirmed a “buy” rating and set a $48.00 price target on shares of Abbott Laboratories in a research report on Saturday, June 18th. Argus reaffirmed a “buy” rating and set a $55.00 price target on shares of Abbott Laboratories in a research report on Thursday, July 28th. TheStreet lowered Abbott Laboratories to a “hold” rating in a research report on Thursday, May 26th. BTIG Research reissued a “buy” rating and issued a $45.00 target price on shares of Abbott Laboratories in a research report on Wednesday, August 10th. Finally, Edward Jones raised Abbott Laboratories from a “hold” rating to a “buy” rating in a research report on Tuesday, June 21st. Seven equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $47.08.

The stock has a market cap of $61.87 billion and a PE ratio of 27.78. The stock has a 50-day moving average price of $43.83 and a 200-day moving average price of $40.92.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Wednesday, July 20th. The healthcare product maker reported $0.55 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.53 by $0.02. The company had revenue of $5.30 billion for the quarter, compared to the consensus estimate of $5.24 billion. The business’s revenue was up 3.2% on a year-over-year basis. During the same period in the prior year, the firm posted $0.52 EPS. Analysts predict that Abbott Laboratories will post $2.20 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 15th. Investors of record on Friday, July 15th were paid a $0.26 dividend. This represents a $1.04 dividend on an annualized basis and a yield of 2.47%. The ex-dividend date of this dividend was Wednesday, July 13th.

In related news, insider Stephen R. Fussell sold 41,500 shares of the business’s stock in a transaction that occurred on Thursday, July 28th. The shares were sold at an average price of $45.00, for a total value of $1,867,500.00. Following the completion of the transaction, the insider now owns 196,467 shares of the company’s stock, valued at $8,841,015. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Chairman Miles D. White acquired 242,547 shares of Abbott Laboratories stock in a transaction that occurred on Monday, July 25th. The stock was acquired at an average cost of $43.18 per share, with a total value of $10,473,179.46. Following the purchase, the chairman now directly owns 2,010,517 shares of the company’s stock, valued at $86,814,124.06. The disclosure for this purchase can be found here.

A number of institutional investors have modified their holdings of the company. Montag A & Associates Inc. increased its position in shares of Abbott Laboratories by 1.7% in the fourth quarter. Montag A & Associates Inc. now owns 64,376 shares of the healthcare product maker’s stock worth $2,891,000 after buying an additional 1,060 shares during the period. Farr Miller & Washington LLC DC increased its position in shares of Abbott Laboratories by 0.8% in the fourth quarter. Farr Miller & Washington LLC DC now owns 470,852 shares of the healthcare product maker’s stock worth $21,146,000 after buying an additional 3,888 shares during the period. Investment Management of Virginia LLC increased its position in shares of Abbott Laboratories by 3.8% in the fourth quarter. Investment Management of Virginia LLC now owns 111,116 shares of the healthcare product maker’s stock worth $4,990,000 after buying an additional 4,098 shares during the period. Autus Asset Management LLC increased its position in shares of Abbott Laboratories by 5.4% in the fourth quarter. Autus Asset Management LLC now owns 99,700 shares of the healthcare product maker’s stock worth $4,478,000 after buying an additional 5,126 shares during the period. Finally, Ancora Advisors LLC increased its position in shares of Abbott Laboratories by 11.7% in the fourth quarter. Ancora Advisors LLC now owns 50,506 shares of the healthcare product maker’s stock worth $2,274,000 after buying an additional 5,300 shares during the period.

Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a line of healthcare products. The Company operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.